Although recent studies suggest that B7-H3 shows significant potential as a treatment target for patients with several different types of solid malignancies and aberrant B7-H3 expression has been documented in various human cancers (Benzon et al., 2017; Nehama et al., 2019; Carvajal-Hausdorf et al., 2019b; Cai et al., 2020),, a comprehensive analysis of B7-H3 expression in PTC had not been performed prior to this study. This evidence concerns the gene CD276 and cancer.